Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Discovery Grants Program - Individual

University of Ottawa

$20,000.00

Chemical synthesis and rationale design of novel peptide and nonpeptide based small molecule inhibitors of SKI-1

FY 2008-09

Summary
Subtilisin Kexin Isozyme-1 (SKI-1) is an enzyme found within cellular compartments of various tissues of mammalian systems, including human. This enzyme cuts larger, inactive protein molecules at specific positions, to generate functionally active smaller protein forms that play important roles in various health conditions and diseases, including viral infections and cholesterol synthesis. In all cases, an increase of enzyme activity causes the formation of a higher level of biologically active cleaved product that eventually contributes to the initiation or progression of the disease. Therefore, one way of managing the disease will be to lower the activity of the enzyme via the application of compounds or agents that interact or bind with the enzyme, thereby blocking its activity. In fact this approach has been applied for intervention of many diseases including hypertension, arthritis, asthma and AIDS. For more than a decade, our laboratory has been studying the structure, function and activity of several enzymes, including SKI-1. In this proposal we would like to make compounds that are capable of destroying or inhibiting the ability of the SKI-1 enzyme to cut inactive large proteins to their small functionally active forms. Thus, we will prepare several molecules based on various strategies with appropriate geometry so that they can bind to SKI-1 and make it less efficient in cutting large proteins. In theory these chemical compounds will find important applications, not only to study the function and mechanism of action of SKI-1 enzyme, but also as possible therapeutic agents. This research will therefore contribute to a better understanding of the importance of SKI-1 in certain diseases and could lead to novel lead compounds with important therapeutic values.
Program
Discovery Grants Program - Individual
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data

As published

Application id
238547-2007
Name nom
Basak, Ajoy
Department département
Medicine, Faculty of
Organization id
28
Institution établissement
University of Ottawa
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2008
Competition year année de concours
2007
Award amount
20000
Program id
RGPIN
Program nane en
Discovery Grants Program - Individual
Program name fr
Programme de subventions à la découverte - individuelles
Group en
Discovery grants programs
Group fr
Programmes de subventions à la découverte
Committee code
24
Committee name en
Inorganic & Organic Chemistry
Committee name fr
Chimie inorg. et org.
Area of application code
1201
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Life sciences (including biotechnology)
Area of application fr
Sciences de la vie (y compris biotechnologie)
Research subject code
5403
Research subject group en
Biochemistry
Research subject group fr
Biochimie
Research subject en
Proteins and peptides, amino acids
Research subject fr
Protéines et peptides, acides aminés
Partie
2
Nb partie
2
Application title
Chemical synthesis and rationale design of novel peptide and nonpeptide based small molecule inhibitors of SKI-1
Keyword
NA
Application summary
Subtilisin Kexin Isozyme-1 (SKI-1) is an enzyme found within cellular compartments of various tissues of mammalian systems, including human. This enzyme cuts larger, inactive protein molecules at specific positions, to generate functionally active smaller protein forms that play important roles in various health conditions and diseases, including viral infections and cholesterol synthesis. In all cases, an increase of enzyme activity causes the formation of a higher level of biologically active cleaved product that eventually contributes to the initiation or progression of the disease. Therefore, one way of managing the disease will be to lower the activity of the enzyme via the application of compounds or agents that interact or bind with the enzyme, thereby blocking its activity. In fact this approach has been applied for intervention of many diseases including hypertension, arthritis, asthma and AIDS. For more than a decade, our laboratory has been studying the structure, function and activity of several enzymes, including SKI-1. In this proposal we would like to make compounds that are capable of destroying or inhibiting the ability of the SKI-1 enzyme to cut inactive large proteins to their small functionally active forms. Thus, we will prepare several molecules based on various strategies with appropriate geometry so that they can bind to SKI-1 and make it less efficient in cutting large proteins. In theory these chemical compounds will find important applications, not only to study the function and mechanism of action of SKI-1 enzyme, but also as possible therapeutic agents. This research will therefore contribute to a better understanding of the importance of SKI-1 in certain diseases and could lead to novel lead compounds with important therapeutic values.